🔍

Jenburkt Pharmaceuticals Ltd (524731)

📊 BSE: 524731 🏢 Pharmaceuticals 📢 Latest filing: 22 Sep 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Jenburkt Pharmaceuticals' revenue was ₹35.5 Cr (-1.4% year on year, -21.1% on the previous quarter), and net profit ₹5.9 Cr (-26.4% year on year); the operating margin was 17.0%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹35.5	-1.4%	-21.1%
Operating profit	₹6.0	-33.0%	-57.0%
Net profit	₹5.9	-26.4%	-46.5%
EPS (₹)	13.34	-24.4%	-45.7%
Operating margin	17.0%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Jenburkt Pharma Equity Shares Admitted Under NSE 'Permitted To Trade' Category

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 22 Sep 2026, 01:20 PM

Jenburkt Pharmaceuticals clarified that its equity shares were admitted to dealings on the Capital Market Segment of the NSE under the 'Permitted to Trade' category effective August 17, 2026, pursuant to NSE Circular NSE/CML/75748 dated August 14, 2026. The company noted it has not applied for an official direct listing on the NSE, and its shares continue to remain officially listed on the BSE. Jenburkt became aware of this development subsequently, as no prior direct communication was received from the NSE.

Admitted to trade on NSE under 'Permitted to Trade' category effective August 17, 2026
Action initiated via NSE Circular No. NSE/CML/75748 dated August 14, 2026
Company confirmed it has not applied for formal equity listing on the NSE
Primary exchange listing continues unchanged on BSE Ltd (Scrip Code: 524731)

💡 Monitor trading liquidity and volume trends across BSE and NSE segments; this is an administrative update with no operational or financial impact.

24.4% YoY PAT Decline to ₹5.89 Cr; Revenue Stagnant at ₹35.51 Cr

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 06 Aug 2026, 08:05 PM

Jenburkt Pharmaceuticals reported a weak Q1 FY27 with Profit After Tax (PAT) declining 24.4% YoY to ₹5.89 Cr, down from ₹7.79 Cr in the year-ago period. Revenue from operations remained virtually flat at ₹35.51 Cr compared to ₹35.53 Cr YoY, while sequentially it dropped 20.4% from ₹44.63 Cr in March 2026. The profitability was severely impacted by a 10.4% YoY increase in total expenses, specifically driven by higher employee costs and other operating expenses. Consequently, the EPS for the quarter fell to ₹13.34 from ₹17.66 YoY.

Net Profit (PAT) fell 24.4% YoY to ₹5.89 Cr from ₹7.79 Cr.
Revenue from operations was stagnant at ₹35.51 Cr vs ₹35.53 Cr in the same quarter last year.
Other expenses surged 21.7% YoY to ₹10.14 Cr from ₹8.33 Cr.
Employee benefit expenses increased 11.1% YoY to ₹13.03 Cr.
Profit Before Tax (PBT) margin contracted significantly to 18.3% from 27.1% YoY.

💡 Investors should monitor the company's ability to manage rising operating costs and employee expenses, which are currently outpacing revenue growth. Watch for updates on international expansion and new product launches to see if they can revitalize the stagnant top-line.

24.4% YoY PAT Decline in Q1 FY27; Revenue Stagnant at ₹35.51 Cr

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 06 Aug 2026, 07:59 PM

Jenburkt Pharmaceuticals reported a weak start to FY27 with Net Profit (PAT) declining 24.4% YoY to ₹5.89 Cr. Revenue from operations remained flat at ₹35.51 Cr compared to ₹35.53 Cr in the year-ago period. Profitability was significantly impacted by a 21.7% rise in other expenses and an 11.1% increase in employee benefit costs. Sequentially, revenue saw a sharp 20.4% drop from the ₹44.63 Cr recorded in the March 2026 quarter.

Revenue from operations remained stagnant at ₹35.51 Cr vs ₹35.53 Cr YoY.
Net Profit (PAT) fell to ₹5.89 Cr, a 24.4% decline from ₹7.79 Cr in Q1 FY26.
Employee benefit expenses rose to ₹13.03 Cr, representing 36.7% of revenue.
Other expenses increased by ₹1.81 Cr YoY to reach ₹10.14 Cr.
Basic EPS for the quarter dropped to ₹13.34 from ₹17.66 YoY.

💡 Investors should monitor the company's ability to control rising operational costs and track if the sequential revenue drop is seasonal or indicative of slowing demand in key therapeutic segments.

₹20.70 Dividend Proposed; AGM Set for Sept 4, 2026; CWIP at ₹46.12 Cr

🟡 NEUTRAL ⭐ 5/10

ROUTINE 📅 03 Aug 2026, 03:55 PM

Jenburkt Pharmaceuticals has scheduled its 41st AGM for September 4, 2026, and proposed a dividend of ₹20.70 per share (207% of face value). For FY26, the company reported revenue of ₹168.74 Cr, an 11% increase YoY, with a PAT of ₹34.74 Cr. A significant highlight is the Capital Work in Progress (CWIP) of ₹46.12 Cr, which represents approximately 27% of FY26 revenue, indicating substantial ongoing investment in modernization. The company remains virtually debt-free with a net worth of ₹197.04 Cr.

Proposed dividend of ₹20.70 per equity share for the financial year ended March 31, 2026.
FY26 Revenue from operations grew to ₹168.74 Cr from ₹151.69 Cr in the previous year.
Capital Work in Progress (CWIP) stands at ₹46.12 Cr, representing 23.4% of the company's Net Worth.
Re-appointment of Shri Dilip H. Bhuta (74 years) as Whole Time Director and CFO for a 5-year term starting April 2027.
Total investments increased to ₹27.02 Cr in FY26 from ₹20.56 Cr in FY25.

💡 Investors should monitor the timeline for the conversion of the ₹46.12 Cr CWIP into operational assets, as this modernization is key to maintaining the company's 27% ROCE.

₹20.70 Dividend Declared; FY26 Revenue Grows 11% to ₹168.7 Cr with Significant CWIP

🟡 NEUTRAL ⭐ 5/10

ROUTINE 📅 03 Aug 2026, 03:12 PM

Jenburkt Pharmaceuticals has released its FY26 Annual Report, confirming a dividend of ₹20.70 per share (207% on face value). The company reported an 11.2% YoY revenue growth to ₹168.74 Cr and an 8.4% increase in PAT to ₹34.74 Cr. A notable highlight is the Capital Work in Progress (CWIP) of ₹46.12 Cr, which is approximately 23.4% of the company's net worth, indicating substantial ongoing investment in modernization or capacity. The 41st AGM is scheduled for September 4, 2026.

Proposed dividend of ₹20.70 per equity share for FY 2025-26.
Annual revenue from operations increased to ₹168.74 Cr from ₹151.69 Cr in the previous year.
Capital Work in Progress (CWIP) stands at ₹46.12 Cr, significantly higher than Net Fixed Assets of ₹19.46 Cr.
Net worth improved to ₹197.04 Cr as of March 31, 2026, from ₹171.78 Cr in FY25.
Re-appointment of Shri Dilip H. Bhuta as Whole Time Director and CFO for a 5-year term starting April 2027.

💡 Investors should monitor the timeline for the commissioning of the ₹46.12 Cr CWIP, as this represents a major asset expansion that could drive future revenue growth.

Aug 6 Board Meeting to Approve Q1 FY27 Unaudited Financial Results

🟡 NEUTRAL ⭐ 2/10

BOARD_MEETING 📅 29 Jul 2026, 05:29 PM

Jenburkt Pharmaceuticals has scheduled a board meeting on August 6, 2026, to review and approve standalone unaudited financial results for the quarter ended June 30, 2026. The company enters this period following a stable FY26, where it recorded a total revenue of ‡169 crore and a net profit of ‡35 crore. With a current market capitalization of ‡473 crore and a low debt-to-equity ratio of 0.01, the upcoming results will be a key indicator of whether the company can sustain its 25.3% operating margins. Investors should note the previous quarter (March 2026) saw a significant EPS of ‡24.58.

Board meeting scheduled for August 6, 2026, to approve Q1 results.
Financials cover the three-month period ending June 30, 2026.
Company reported a TTM PAT of ‡35 crore leading into this quarter.
Operating profit margin stood at 25.3% for the trailing twelve months.
Promoter holding remains relatively stable at 46.62% as of June 2026.

💡 Monitor the official results release on August 6 to assess if the company is meeting its 8-10% expected growth rate and how NPPA pricing controls are impacting margins.

Jenburkt Pharmaceuticals to Shift Registered Office Effective July 21, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 13 Jul 2026, 06:43 PM

Jenburkt Pharmaceuticals Ltd has announced a change in its registered office address within the local limits of Mumbai. The Board of Directors approved this shift via a circular resolution on July 13, 2026. The relocation from Nirmala Apartments to the 14th floor of the Unicorn building in Andheri West will be effective from July 21, 2026. This is a purely administrative move with no changes to the Registrar of Companies (ROC) jurisdiction or the company's contact details.

Registered office shifting effective from July 21, 2026
Board approval obtained via circular resolution on July 13, 2026
Relocation is within the local limits of Mumbai (Andheri West)
New office located on the 14th floor of the Unicorn building

💡 No action is required from investors as this is a routine administrative update. Ensure any physical correspondence after July 21, 2026, is directed to the new address.

View All 524731 Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates exclusively in the pharmaceutical formulations segment, which generated total revenue of INR 15,841.25 Lacs in FY 2024-25, representing a growth of 8.03% YoY from INR 14,663.34 Lacs in FY 2023-24.

Geographic Revenue Split

Not specifically disclosed by percentage, but the company maintains a presence in both domestic Indian markets and international regions, noting a temporary slowdown in certain international markets due to currency fluctuations and import restrictions.

Profitability Margins

Operating profit margin improved significantly from 25.05% in FY 2023-24 to 29.32% in FY 2024-25. Net profit margin also saw an upward trend, increasing from 18.30% to 21.14% over the same period due to better operational philosophy and performance-driven models.

EBITDA Margin

Operating profit margin (a proxy for core profitability) stood at 29.32% for FY 2024-25, a YoY increase of 427 basis points from 25.05%, driven by a strategic organizational refresh and improved agility.

Capital Expenditure

Not disclosed in absolute INR Cr; however, the company states that profits are ploughed back into the business every year to fund strategic and diversified investments, research and development, and sustainable growth.

Credit Rating & Borrowing

CRISIL withdrew the rating for bank loan facilities of INR 70 Million in 2014 at the company's request as there were no outstanding dues. The company remains virtually debt-free with a total Debt-Equity Ratio of only 0.02 times in FY 2024-25.

⚙️ Operational Drivers

Raw Materials

Active Pharmaceutical Ingredients (APIs) are the primary raw materials; specific percentage of total cost is not disclosed, but they represent the core input for pharmaceutical formulations.

Import Sources

China is specifically identified as a critical source for Active Pharmaceutical Ingredients (APIs), creating a strategic vulnerability due to potential export restrictions.

Capacity Expansion

Current installed capacity is not disclosed in MT/units; however, the company is modernizing operations through the Revamped Pharmaceuticals Technology Upgradation Assistance Scheme (RPTUAS) to meet international standards.

Raw Material Costs

Not disclosed as a specific percentage of revenue; however, the company notes that dependence on China for APIs could escalate costs by 20-30% if supply disruptions or resource nationalism occur.

Manufacturing Efficiency

The company operates a manufacturing unit at Sihor, Gujarat; specific utilization percentages are not disclosed, but the company is implementing Artwork Management software to digitize manual processes and reduce approval timelines.

Logistics & Distribution

Not disclosed as a specific percentage of revenue; however, the company emphasizes prompt payment to vendors to ensure a smooth supply chain.

📈 Strategic Growth

Expected Growth Rate

8-10%

Growth Strategy

Growth will be achieved through a strategic organizational refresh focused on Teamwork, Performance, and Agility. This includes launching new products (4 launched in FY 2024-25), international expansion, and digital transformation via AI/ML in drug discovery and Artwork Management software to reduce operational lead times.

Products & Services

Speciality pharmaceutical formulations, healthcare products, and medicines focused on pain management, oncology, neurology, and chronic diseases.

Brand Portfolio

Jenburkt

New Products/Services

Launched 2 new products in the Pharmaceutical Division and 2 new products in the Wellness Division during FY 2024-25.

Market Expansion

Focusing on international business prospects and becoming a globally recognized healthcare brand by engaging with local partners in export markets.

Market Share & Ranking

Not disclosed; however, India as a whole accounts for 20% of global generic medicine volume.

Strategic Alliances

Engaging with local partners in international markets to ensure business continuity despite temporary demand slowdowns.

🌍 External Factors

Industry Trends

The industry is shifting toward innovation, complex therapies, and digital transformation. The domestic biosimilars market is projected to grow at a 14% CAGR, and the 'China+1' strategy is attracting more contract manufacturing to India.

Competitive Landscape

The industry comprises over 3,000 drug manufacturers; Jenburkt competes on quality and compliance, leveraging its USFDA-approved plant environment in India.

Competitive Moat

Moat is built on 40 years of excellence, a debt-free and cash-rich balance sheet (Net Worth of INR 17,177.71 Lacs), and a renewed R&D certification which provides scientific credibility and financial agility to seize growth opportunities.

Macro Economic Sensitivity

Sensitive to government healthcare spending and the 'Digital Health Blueprint' initiatives; the domestic market is projected to reach USD 58 billion by 2025.

Consumer Behavior

Shifting toward chronic disease treatments and affordable biosimilars due to an aging population and changing disease burden in India.

Geopolitical Risks

Dependence on China for APIs and resource nationalism are cited as major risks that could disrupt production capabilities.

⚖️ Regulatory & Governance

Industry Regulations

Subject to Drugs and Cosmetics Act 1940, Drug (Price Control) Order 2013, and CDSCO quality control measures. The government recently banned 156 fixed-dose combination (FDC) drugs.